Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31361425 | 1.00 | BCHE (0.60) | BCHEMAPK1HSD17B10SMPD1HDAC1 | |
| SCHEMBL31725848 | 0.94 | NPC1 (0.63) | BCHEHSD17B10ABCB1ABCG2KDM4E | |
| SCHEMBL698056 | 0.94 | NPC1 (0.63) | BCHEHSD17B10ABCB1ABCG2KDM4E | |
| SCHEMBL584781 | 0.90 | SLC2A1 (0.56) | BCHEHSD17B10HTTSMN1; SMN2KMT2A | |
| SCHEMBL30280404 | 0.90 | SLC2A1 (0.56) | BCHEHSD17B10HTTSMN1; SMN2KMT2A | |
| SCHEMBL12296058 | 0.88 | BCHE (0.61) | BCHEMAPK1HSD17B10SMPD1HDAC1 | |
| SCHEMBL6489381 | 0.87 | NPC1 (0.56) | BCHESMPD1KDM4ELMNAHTT | |
| SCHEMBL6035606 | 0.86 | MEN1 (0.60) | MAPK1HSD17B10KDM4ELMNAHTT | |
| SCHEMBL8554822 | 0.85 | MAPK1 (0.64) | BCHEMAPK1HSD17B10SMPD1HDAC1 | |
| SCHEMBL5753220 | 0.85 | SRD5A1 (0.53) | BCHESMPD1HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113999232-B | MAT2A inhibitors | 南京正大天晴制药有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-113999232-A | MAT2A inhibitors | 南京正大天晴制药有限公司 | 2022-02-01 | — | — | CN | disclosed |
| EP-3689817-A1 | PROCESS FOR PRODUCING HYDROGEN OR HEAVY HYDROGENS, AND HYDROGENATION (PROTIATION, DEUTERATION OR TRITIATION) OF ORGANIC COMPOUNDS USING SAME | Shiono Chemical Co., Ltd. (JP) | 2020-08-05 | — | — | EP | disclosed |
| EP-2607300-B1 | PROCESS FOR HYDROGENATION OF ORGANIC COMPOUNDS USING HYDROGEN OR HEAVY HYDROGEN | SHIONO CHEMICAL CO LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-2607300-B1 | PROCESS FOR HYDROGENATION OF ORGANIC COMPOUNDS USING HYDROGEN OR HEAVY HYDROGEN | SHIONO CHEMICAL CO LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| US-9708310-B2 | Phenanthroindolizidine and phenanthroquinolizidine alkaloid having a hydroxyl group on the phenanthrene ring thereof, preparation method and use thereof | CHINA MEDICAL UNIVERSITY (TW) | 2017-07-18 | — | — | US | disclosed |
| US-9708310-B2 | Phenanthroindolizidine and phenanthroquinolizidine alkaloid having a hydroxyl group on the phenanthrene ring thereof, preparation method and use thereof | CHINA MEDICAL UNIVERSITY (TW) | 2017-07-18 | — | — | US | disclosed |
| US-9676622-B2 | Process for producing hydrogen or heavy hydrogens, and hydrogenation (protiation, deuteration or tritiation) of organic compounds using same | SHIONO CHEMICAL CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-9676622-B2 | Process for producing hydrogen or heavy hydrogens, and hydrogenation (protiation, deuteration or tritiation) of organic compounds using same | SHIONO CHEMICAL CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-20170152257-A1 | PHENANTHROINDOLIZIDINE AND PHENANTHROQUINOLIZIDINE ALKALOID HAVING A HYDROXYL GROUP ON THE PHENANTHRENE RING THEREOF, PREPARATION METHOD AND USE THEREOF | CHINA MEDICAL UNIVERSITY (TW) | 2017-06-01 | — | — | US | disclosed |
| US-6228859-B1 | ANTIASTHMATIC, ANTIINFLAMMATORY, ANTIALLERGEN AND ANTIDEPRESSANT AGENTS | EURO-CELTIQUE S.A. (LU) | 2001-05-08 | — | — | US | disclosed |
| WO-2001011967-A1 | NOVEL HYPOXANTHINE AND THIOHYPOXANTHINE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2001-02-22 | — | — | WO | disclosed |
| EP-1045849-A1 | PURINE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITION ACTIVITY | Euro-Celtique S.A. (LU) | 2000-10-25 | — | — | EP | disclosed |
| US-6071945-A | ANTICARCINOGENIC OR ANTITUMOR AGENTS | ADIR ET COMPAGNIE (FR) | 2000-06-06 | — | — | US | disclosed |
| EP-0982308-A1 | Derivatives of the 8H-(2,3-b)-pyrrolizine-8-one, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2000-03-01 | — | — | EP | disclosed |
| CN-1244529-A | Novel 8H-thiophene [2,3-b] pyrrolinezine-8-on compound, its preparing method and their medicinal compounds containing them | ADIR (FR) | 2000-02-16 | — | — | CN | disclosed |
| WO-1999031102-A1 | PURINE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITION ACTIVITY | EURO-CELTIQUE, S.A. (LU) | 1999-06-24 | — | — | WO | disclosed |
| EP-0183216-B1 | N-(ARALKOXYBENZYL)-4(BENZHYDRYL) PIPERIDINES | G.D. Searle & Co. (US) | 1989-07-19 | — | — | EP | disclosed |
| US-4650874-A | CARDIOVASCULAR AGENTS | G. D. SEARLE & CO. (US) | 1987-03-17 | — | — | US | disclosed |
| EP-0183216-A1 | N-(Aralkoxybenzyl)-4(benzhydryl) piperidines | G.D. Searle & Co. (US) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152257-A1 | PHENANTHROINDOLIZIDINE AND PHENANTHROQUINOLIZIDINE ALKALOID HAVING A HYDROXYL GROUP ON THE PHENANTHRENE RING THEREOF, PREPARATION METHOD AND USE THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAH, HIPK4 | BCHE 176/4885MAPK1 3795/4885HSD17B10 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.